"Drug Duo Speeds Regeneration of Key Cells Lost in Diabetes" - Serena Gordon
A novel combination of two drugs appeared to spur faster regeneration of insulin-producing beta cells in the pancreas, a preliminary study in mice and human tissue found. Beta cells are crucial to making insulin, a hormone that's deficient in people with type 1 and type 2 diabetes. The new drug combo pairs an already approved class of type 2 diabetes medications called GLP-1 receptor agonists with an experimental drug called harmine. "In the United States, 30 million people have diabetes. As many as 80 million have prediabetes. Worldwide, there are 400 million people with diabetes. All of those people have inadequate numbers of beta cells," explained senior study author Andrew Stewart, MD, director of the Mount Sinai Diabetes, Obesity and Metabolism Institute at the Icahn School of Medicine at Mount Sinai.
— Andrew Stewart, MD, Professor, Medicine, Endocrinology, Diabetes and Bone Disease, Director, Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai
Additional coverage: Medical Research;Gen&Biotechnology News; Crain’s Health Pulse; U.S News & World Report; Fierce Biotech; Benzinga
Mount Sinai Researchers Move Closer to a Cure for Diabetes
Dec 10, 2024 View All Press Releases
SARS-CoV-2 Infection Likely Not Associated With Increased Risk of New-Onset Diabetes
Feb 22, 2022 View All Press ReleasesMount Sinai Discovers New Drug Combo to Induce High Rates of Human Beta Cell Regeneration
Feb 12, 2020 View All Press Releases